Structure Therapeutics (GPCR) Other Non-Current Liabilities (2023 - 2026)
Structure Therapeutics (GPCR) recorded quarterly Other Non-Current Liabilities of $863000.0 in Q1 2026, up 33.38% quarter-over-quarter from $647000.0 in Q4 2025, and up 180.19% on a YoY basis from $308000.0 in Q1 2025.
Structure Therapeutics (GPCR) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Structure Therapeutics' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $863000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 180.19% year-over-year to $863000.0; the TTM figure through Mar 2026 stood at $863000.0 (up 180.19% YoY), while the FY2025 annual figure was $647000.0, up 114.24% from the prior year.
- Other Non-Current Liabilities was $863000.0 for Q1 2026 at Structure Therapeutics, up from $647000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $863000.0 in Q1 2026 to a low of $281000.0 in Q3 2023.
- Historically, Other Non-Current Liabilities has averaged $403727.3 across 4 years, with a median of $309000.0 in 2024.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities plunged 39.6% in 2024, then jumped 180.19% in 2026.
- A 4-year view of Other Non-Current Liabilities shows it stood at $500000.0 in 2023, then slumped by 39.6% to $302000.0 in 2024, then jumped by 114.24% to $647000.0 in 2025, then soared by 33.38% to $863000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $863000.0 (Q1 2026), $647000.0 (Q4 2025), and $325000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Structure Therapeutics | 9.35 Bn | 9.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 863,000.00 |
| Dec 31, 2025 | 647,000.00 |
| Sep 30, 2025 | 325,000.00 |
| Jun 30, 2025 | 317,000.00 |
| Mar 31, 2025 | 308,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Sep 30, 2024 | 309,000.00 |
| Jun 30, 2024 | 293,000.00 |
| Mar 31, 2024 | 296,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 281,000.00 |